Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
== Biography == Tanner joined SCIEX, which later became MDS SCIEX, in 1980 as a research scientist. He became principal scientist in 2000. In his 25 years at SCIEX, Tanner developed and helped to commercialize a string of mass spectrometry products. Tanner published over 74 peer-reviewed scientific articles, and holds 22 US patents (with corresponding filings in other countries), including 13 patents on Mass Cytometry technology Tanner was a co-founder of DVS Sciences and, as the president and CEO, saw the company through the development and commercial launch of its first products. The products that DVS Sciences brought to the global market were originally developed at the University of Toronto where Tanner was a professor in the Institute of Biomaterials and Biomedical Engineering and then in chemistry.
LG CNS Co., Ltd. (Korean: 주식회사 엘지씨엔에스) is a South Korean technology company offering services in artificial intelligence, robotics, cloud computing, smart factories, smart logistics, system integration, and IT Outsourcing (ITO).
The 1848 appointment of Lord Dalhousie as the Governor General of the East India Company set the stage for changes essential to a modern state: consolidating and demarcating sovereignty, monitoring the population through censuses, educating citizens and rationalising the beauraucracy. Technological advancements—among them, railways, canals, and the telegraph—were introduced within years of their introduction in Europe, with the East India Company guaranteeing fixed financial returns to attract British private investors. Simultaneously, the proponents of these public works lobbied the British government for support, presenting them as necessities for military logistics and security and Indian social and cultural reform. Thus, the Upper Doab's Ganges Canal—conceived by Proby Cautley under Lord Auckland and completed under Dalhousie—was promoted to Company's Court of Directors in London as both a vital relief response to the Agra famine of 1837–1838 and a revenue-generating irrigation and navigation project. The canal, which brought agricultural prosperity to some areas, ultimately caused soil salinisation in others. Disaffection with the company also grew during this time, culminating in the Indian Rebellion of 1857, which swept across the central Gangetic plain, and extended into Central India. Shaking the foundations of Company rule, the uprising was provoked by diverse resentments and perceptions, including invasive British-style social reforms, harsh land taxes, and summary treatment of some wealthy landowners and princes.
Bovista – various species, including: Bovista aestivalis Bovista dermoxantha Bovista nigrescens Bovista plumbea Calvatia – various species, including: Calvatia bovista Calvatia craniiformis Calvatia cyathiformis Calvatia gigantea Calvatia booniana Calvatia fumosa Calvatia lepidophora Calvatia pachyderma Calvatia sculpta Calvatia subcretacea – edible Calbovista subsculpta Handkea – various species, including: Handkea utriformis Lycoperdon – various species, including: Lycoperdon candidum Lycoperdon echinatum Lycoperdon fusillum Lycoperdon umbrinum Scleroderma – various species, including: Scleroderma auratium Scleroderma geaster – not edible
Sources: en.wikipedia.org
=== Host restriction and safety for domestic animals === Currently, there is no scientific data obtained using modern detection methods that would identify SeV as an infectious - disease causing agent for humans or domestic animals. Modern methods for the identification of pathogenic microorganisms have never detected SeV in pigs or other domestic animals, despite the isolation of other paramyxoviruses. Consequently, it is recognized that Sendai virus disease causing infection is host restrictive for rodents and the virus does not cause disease in humans or domestic animals, which are natural hosts for their own parainfluenza viruses. After experimental SeV infection the virus can replicate and shed from the upper and lower respiratory tract of African green monkeys and chimpanzees, but it is not causing any disease. Sendai virus has been used and demonstrated high safety profile in clinical trials involving both adults and children to immunize against human parainfluenza virus type 1, since the two viruses share common antigenic determinants and trigger the generation of cross-reactive neutralizing antibodies. The study that was published in 2011 demonstrated that SeV neutralizing antibodies (which were formed due to human parainfluenza virus type 1 past infection) can be detected in 92.5% of human subjects worldwide with a median EC50 titer of 60.6 and values ranging from 5.9 to 11,324. Low anti-SeV antibodies background does not block the ability of SeV-base vaccine to promote antigen-specific T cell immunity.
Scott in 1951 published a protocol described as "the advent of the modern blood culture set". Scott's method involved inoculating blood into two rubber-sealed glass bottles; one for aerobes and one for anaerobes. The aerobic bottle contained trypticase soy broth and an agar slant, and the anaerobic bottle contained thioglycollate broth. The lysis-centrifugation method was introduced in 1917 by Mildred Clough, but it was rarely used in clinical practice until commercial systems were developed in the mid-1970s. Automated blood culture systems first became available in the 1970s. The earliest of these—the BACTEC systems, produced by Johnston Laboratories (now Becton Dickinson)—used culture broths containing nutrients labelled with radioactive isotopes. Microbes that fed on these substrates would produce radioactive carbon dioxide, and growth could be detected by monitoring its concentration. Before this technique was applied to blood cultures, it had been proposed by NASA as a method for detecting life on Mars. Throughout the 1970s and 80s several manufacturers attempted to detect microbial growth by measuring changes in the electrical conductivity of the culture medium, but none of these methods were commercially successful. A major issue with the early BACTEC systems was that they produced radioactive waste, which required special disposal procedures, so in 1984 a new generation of BACTEC instruments was released that used spectrophotometry to detect CO2.
=== President and Past Presidents (since 1953) === 2022–2024 Julia Laskin 2020–2022 Susan Richardson 2016–2018 Vicki Wysocki 2014–2016 Jennifer Brodbelt 2012–2014 Susan Weintraub 2006–2008 Barbara S. Larsen 2002–2004 Catherine E. Costello 1996–1998 Veronica M. Bierbaum 1982–1984 Catherine Fenselau
== History == Ferric maltol was approved for medical use in the European Union in February 2016. Ferric maltol was approved for medical use in the United States in July 2019, based on evidence from three clinical trials (NCT01340872, NCT01352221, and NCT02968368). All 295 participants had low iron stores in the body and consequent iron deficiency anemia. In the first two trials low iron was caused by participants' inflammatory bowel disease and in the last trial, by long standing (chronic) kidney disease. Trials were conducted at 79 sites in Europe and the United States. The efficacy of ferric maltol to treat iron deficiency in people aged 10-17 years of age was assessed in the FORTIS trial (NCT05126901). The trial treated 24 participants with age-based dosing of ferric maltol twice daily, and showed a clinically meaningful average increase in hemoglobin of 1.1 g/dL at week 12. This, on average, would be the expected increase in hemoglobin with one blood transfusion.
== Chemical properties == myo-Inositol is a meso compound, meaning it is optically inactive because it has a plane of symmetry. It is a white crystalline powder, relatively stable in the air. It is highly soluble in water, slightly soluble in glacial acetic acid, ethanol, glycol, and glycerin, but insoluble in chloroform and ether. In its most stable conformation, the myo-inositol isomer assumes the chair conformation, which moves the maximum number of hydroxyls to the equatorial position, where they are farthest apart from each other. In this conformation, the natural myo isomer has a structure in which five of the six hydroxyls (the first, third, fourth, fifth, and sixth) are equatorial, whereas the second hydroxyl group is axial.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.